Program
Flurbiprofen
Also written as “flurbiprofen”, “Flurbiprofen tablet” and “Flurbiprofen 100 mg”.
Its studies are mostly in Pharyngitis · HIV Infections · Diabetes Mellitus, Type 2 · Anemia · Periodontitis, led by 7 companies.
Drug pageFlurbiprofen: every studyMany companies study it; this page follows only the 12 they lead. All 31 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 40 open or running | phase 1since Mar 1, 2007 | Mar 1, 2007 | none ahead |
| Reckittits history only | 30 open or running | phase 3since Jan 13, 2010 | Jan 13, 2010 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 1since Aug 26, 2014 | Aug 26, 2014 | none ahead |
| Dexcel Pharma Technologiesits history only | 10 open or running | phase 2since Dec 27, 2009 | Dec 27, 2009 | none ahead |
| Idorsia Pharmaceuticalsits history only | 10 open or running | phase 1since Feb 15, 2022 | Feb 15, 2022 | none ahead |
| Institut de Recherches Internationales Servier (I.R.I.S.)its history only | 10 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | none ahead |
| Teikoku Seiyakuits history only | 10 open or running | phase 1since Jan 19, 2025 | Jan 19, 2025 | none ahead |
Also a collaborator on its studies: SocraMetrics and HWI pharma services.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 1, 2007First study: phase 1 study in AnemiaFirst studyNCT00443170 · 90 enrolled · Australia
- Feb 1, 2008Phase 1 study in Diabetes Mellitus, Type 2NCT00615212 · 23 enrolled · United States
- Jul 23, 2009Phase 1 study in Drug InteractionsNCT00964106 · 87 enrolled · Korea, Republic of
- Jun 5, 2020Phase 1 study in HIV InfectionsNCT04425902 · 20 enrolled · United States
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
Studies
All 4 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04425902HIV Infections · United States | 1 | Completed | Mar 10, 2021 | 20 |
| NCT00964106Drug Interactions · Korea, Republic of | 1 | Completed | Aug 29, 2011 | 87 |
| NCT00615212Diabetes Mellitus, Type 2 · United States | 1 | Completed | Feb 15, 2008 | 23 |
| NCT00443170Anemia · Australia | 1 | Completed | 90 |
How it is read
Names in the registry
- “Flurbiprofen”, 7 entries
- “flurbiprofen”, 2 entries
- “Flurbiprofen tablet”, 1 entry
- “Flurbiprofen 100 mg”, 1 entry
- “omeprazole, caffeine, flurbiprofen, rosiglitazone”, 1 entry
Conditions, from the studies’ own filings
- Pharyngitis, 3 studies
- HIV Infections, 1 study
- Diabetes Mellitus, Type 2, 1 study
- Anemia, 1 study
- Periodontitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.